Evidence map›Paper›PMID 30603051›Full record

ReviewInflammation and regeneration2018

The impact of senescence-associated T cells on immunosenescence and age-related disorders.

Yuji Fukushima, Nagahiro Minato, Masakazu Hattori

Open access · goldAbstract readReview
In one paragraph

Review in Inflammation and regeneration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Article
  3. T cell senescence induced by DNMT1 deletion mediates cardiac transplant tolerance via altered CDKN1A methylation.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  4. Review
  5. Kidney Disease as a Driver of Immunosenescence: Mechanisms and Potential Interventions.Journal of the American Society of Nephrology : JASN · 2026
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Immunosenescence: signaling pathways, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yuji Fukushima1Department of Immunosenescence, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507 Japan.
Nagahiro Minato2DSK Project, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507 Japan.
Masakazu Hattori1Department of Immunosenescence, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507 Japan.
Kyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunosenescence is age-associated changes in the immunological functions, including diminished acquired immunity against infection, pro-inflammatory traits, and increased risk of autoimmunity. The proportions of memory-phenotype T cells in the peripheral T cell population steadily increase with age, but the relationship between this change and immunosenescent phenotypes remains elusive. Recently, we identified a minor memory-phenotype CD4

Indexed as

Age-related disordersImmunosenescenceOsteopontinSenescence-associated T cellsThymus

Identifiers

PMID30603051
PMCPMC6304761
OpenAlexW2888177948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.